乳がん治療におけるタルゼンナの安全性を検討する研究

基本情報

NCT ID

NCT06735742

ステータス

実施中（募集終了）

試験のフェーズ

-

試験タイプ

観察

目標被験者数

3

治験依頼者名

Pfizer

概要

The purpose of this study is to learn about the safety of TALZENNA for the patients with breast cancer that cannot be removed by surgery and has come back. These participants also have a past treatment with medicines that try to stop the growth of cancer cells. This study is seeking for participants who: * have breast cancer that cannot be removed by surgery and has come back * have not used this medicine before. All patients in this study will receive TALZENNA according to the prescriptions. Patients will be followed up to 52 weeks (12 months) from the day of start of treatment start (Day 1). However, in cases where treatment has been completed or stopped less than 52 weeks (12 months) after the start of giving study medicine, the participants will be checked until completion (discontinuation) of treatment.

対象疾患

依頼者（Sponsor）

実施施設 (1)